On 2024-10-01 18:51:48, user Maria Valle wrote:
This review was done as part of the SfN Reviewer Mentor Program (Mentor: Joanne Conover, PhD; Mentee: Maria Luisa Valle, PhD)
Manuscript title: Human iPSC-derived pericyte-like cells carrying APP Swedish mutation overproduce beta-amyloid and induce cerebral amyloid angiopathy-like changes<br /> Journal: bioRxiv
Overview<br /> Wu et al. characterized human induced pluripotent stem cell (iPSC)-derived pericyte-like cells (iPLCs) to investigate the role of pericytes in Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). First, the authors showed that iPSCs could efficiently differentiate into pericyte-like cells, express pericyte specific markers, and promote angiogenesis, barrier integrity and contractility. They then investigated the differences between iPLCs derived from healthy individuals and those derived from AD patients carrying APPswe mutations. Compared to controls, APPswe iPLCs exhibited a distinct expression of pericyte markers, were able to secrete amyloid beta 1-40 and 1-42 within the media, had an altered transcriptome for key genes involved in cytoskeleton reorganization and metabolic regulation, were more sensitive to mediators of inflammation, and showed compromised angiogenesis, barrier integrity and hypercontractility.<br /> Overall, the manuscript uses a novel approach (iPLCs) to investigate an interesting and sometimes overlooked topic - the specific contribution of pericytes to AD pathology and vascular disfunction. Previous work conducted in in vitro BBB models showed that pericytes play a key role in amyloid clearance contributing to the removal of aggregated A? from brain capillaries (Ma et al, Mol Neurodegeneration 13, 57 (2018) and Blanchard et al, Nat Med. 2020 Jun;26(6):952-963). Here, the authors focus on the contribution of pericytes in amyloid secretion, emphasizing the novelty of their research. However, the high variability within datasets and the small number of replicates raises some concern.
Major comments <br /> • The statement “…overproduce beta-amyloid” in the manuscript title suggests that pericytes have a significant role in A? production. Although the authors showed that APPswe iPLCs could secrete 10 times more A?1-42 than the control cells, the A?1-42 levels are 100 times lower than neurons. Thus, the authors concluded that “contribution of pericytes to total brain amyloid load in AD is limited”. The title should be changed to indicate the main findings of the work and should be supported by the data presented. <br /> • APPswe iPLCs were derive from 3 donors versus iPLCs from 7 healthy controls. Importantly, among the donors, only one had AD, while the others had pre-symptomatic AD or no symptomatology (in this case the mutation was introduced using CRISPR-Cas9 as reported in the methods). The variability in AD cases plus the differences in symptomatology may skew the results and may contribute to the high variability shown in several graphs (Figure 2 A, B, C, F, J).
Figures<br /> • The authors should be consistent in the number of replicates used: different groups in the graphs show only 1 or 2 replicates, even for control cell lines, which makes the reader question the reproducibility and accuracy of their findings (see Figures 1B, 1I, 1K, 2H, 2J, 4E). <br /> • The authors should clarify the findings reported in Figures 2E and 2H: the figures are similar, but it is not clear if iPLCs in 2H derive from APPswe iPLCs (as reported in the figure legend) or control.<br /> • The authors should correct Figures 1A and 2I as sample labels are missing. The authors should also modify the arrows used in Figure 2I and 2D as it is not clear to what they are pointing. Scale bars should be added on both images since they show different magnification. <br /> • Figures should be arranged in a consistent manner e.g., same format and order should be used consistently.
Discussion <br /> • An interesting finding is that the HIF1a pathway is downregulated in APPswe iPLCs (Figure 3B). The authors should mention this finding in the discussion. This finding could also support the fact that APPswe cells have decreased VEGF levels and impaired angiogenesis and no change in BACE1 levels (as VEGF and BACE1 are HIF1a target genes). <br /> • For future experiments, the authors should discuss whether APPswe iPLCs exhibit differences in oxidative stress, ROS production and mitochondrial activity compared to controls.<br /> • For future experiments, the authors should use cell lines and human-derived cells as models as they may reveal differences from iPLCs.
Minor comments<br /> • The authors measured the changes in expression of several pericytes associated genes in Figure 1. However, it is not clear why the authors were not consistent with these specific genes for their further analysis. For example, in Figure 1B they measured PDGFRB, DES, LAMA2, DLC1, and PDE7B while in 1C they measured LAMA2, PDE7B, DES, omitting PDGFRB but adding genes ACTA2 and CD248. Then, all genes were analyzed in Figure 2A-B. Thus, the authors should provide change in expression data for all genes (PDGFRB, LAMA2, DLC1, CD248, PDE7B, ACTA2, DES) in 1B and 1C or provide reasoning for leaving some out. <br /> • Please correct the repeated sentences on page 5: “…which are known to express detectable levels of LRP121 (Figure 2 J). Furthermore, when iPLCs were subjected to pHrodo-conjugated zymosan-coated beads, no uptake of these pathogen-mimicking particles was observed (data not shown). Thus, it appears that the phagocytic activity of these iPLCs is low.”<br /> • Additional edits for word choice and sentence construction are also needed, e.g., pg 10, 2nd to last paragraph, 2nd to last sentence is awkward.
Decision for the editor: Major revisions<br /> The manuscript presents a novel idea that could advance the AD/CAA field but, at this stage, I have several major concerns regarding reproducibility and possible accuracy of the described findings. I would consider the manuscript for publication only if all major concerns are addressed by the authors.